The Wyss Institute at Harvard Universtiy and Dana-Farber Cancer Institute have entered a licensing and collaboration agreement with Novartis to develop our biomaterial systems to delivery next generation immunotherapies. Our approach uses an injectable or implantable biomaterial scaffold that recruits and trains the body's endogenous immune cells to identify and kill a patient's own cancerous cells. A big congratulations to Dave, Omar, and team! We've still got a lot of work to do.
For more information on our technology, please have a look at the immunotherapy research section.
To view the Novartis press release, click here.
Photo credit: Wyss Institute at Harvard University